GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Devices & Instruments » C-Rad AB (LTS:0R44) » Definitions » ROIC %

C-Rad AB (LTS:0R44) ROIC % : 19.01% (As of Mar. 2024)


View and export this data going back to 2014. Start your Free Trial

What is C-Rad AB ROIC %?

ROIC % measures how well a company generates cash flow relative to the capital it has invested in its business. It is also called ROC %. C-Rad AB's annualized return on invested capital (ROIC %) for the quarter that ended in Mar. 2024 was 19.01%.

As of today (2024-05-30), C-Rad AB's WACC % is 7.40%. C-Rad AB's ROIC % is 19.75% (calculated using TTM income statement data). C-Rad AB generates higher returns on investment than it costs the company to raise the capital needed for that investment. It is earning excess returns. A firm that expects to continue generating positive excess returns on new investments in the future will see its value increase as growth increases.


C-Rad AB ROIC % Historical Data

The historical data trend for C-Rad AB's ROIC % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

C-Rad AB ROIC % Chart

C-Rad AB Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
ROIC %
Get a 7-Day Free Trial Premium Member Only Premium Member Only -7.73 13.43 16.73 4.35 18.62

C-Rad AB Quarterly Data
Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
ROIC % Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 6.12 9.12 17.06 38.43 19.01

Competitive Comparison of C-Rad AB's ROIC %

For the Medical Devices subindustry, C-Rad AB's ROIC %, along with its competitors' market caps and ROIC % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


C-Rad AB's ROIC % Distribution in the Medical Devices & Instruments Industry

For the Medical Devices & Instruments industry and Healthcare sector, C-Rad AB's ROIC % distribution charts can be found below:

* The bar in red indicates where C-Rad AB's ROIC % falls into.



C-Rad AB ROIC % Calculation

C-Rad AB's annualized Return on Invested Capital (ROIC %) for the fiscal year that ended in Dec. 2023 is calculated as:

ROIC % (A: Dec. 2023 )
=NOPAT/Average Invested Capital
=Operating Income * ( 1 - Tax Rate % )/( (Invested Capital (A: Dec. 2022 ) + Invested Capital (A: Dec. 2023 ))/ count )
=49.812 * ( 1 - 19.12% )/( (186.271 + 246.492)/ 2 )
=40.2879456/216.3815
=18.62 %

where

Invested Capital(A: Dec. 2022 )
=Total Assets - Accounts Payable & Accrued Expense - Excess Cash
=Total Assets - Accounts Payable & Accrued Expense - ( Cash, Cash Equivalents, Marketable Securities - max(0, Total Current Liabilities - Total Current Assets+Cash, Cash Equivalents, Marketable Securities))
=339.174 - 31.007 - ( 121.896 - max(0, 92.555 - 307.125+121.896))
=186.271

Invested Capital(A: Dec. 2023 )
=Total Assets - Accounts Payable & Accrued Expense - Excess Cash
=Total Assets - Accounts Payable & Accrued Expense - ( Cash, Cash Equivalents, Marketable Securities - max(0, Total Current Liabilities - Total Current Assets+Cash, Cash Equivalents, Marketable Securities))
=405.536 - 29.683 - ( 129.361 - max(0, 132.603 - 364.617+129.361))
=246.492

C-Rad AB's annualized Return on Invested Capital (ROIC %) for the quarter that ended in Mar. 2024 is calculated as:

ROIC % (Q: Mar. 2024 )
=NOPAT/Average Invested Capital
=Operating Income * ( 1 - Tax Rate % )/( (Invested Capital (Q: Dec. 2023 ) + Invested Capital (Q: Mar. 2024 ))/ count )
=56.8 * ( 1 - 14.81% )/( (246.492 + 262.6)/ 2 )
=48.38792/254.546
=19.01 %

where

Invested Capital(Q: Dec. 2023 )
=Total Assets - Accounts Payable & Accrued Expense - Excess Cash
=Total Assets - Accounts Payable & Accrued Expense - ( Cash, Cash Equivalents, Marketable Securities - max(0, Total Current Liabilities - Total Current Assets+Cash, Cash Equivalents, Marketable Securities))
=405.536 - 29.683 - ( 129.361 - max(0, 132.603 - 364.617+129.361))
=246.492

Note: The Operating Income data used here is four times the quarterly (Mar. 2024) data.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


C-Rad AB  (LTS:0R44) ROIC % Explanation

ROIC % measures how well a company generates cash flow relative to the capital it has invested in its business. It is also called ROC %. The reason book values of debt and equity are used is because the book values are the capital the company received when issuing the debt or receiving the equity investments.

There are four key components to this definition. The first is the use of operating income or EBIT rather than net income in the numerator. The second is the tax adjustment to this operating income or EBIT, computed as a hypothetical tax based on an effective or marginal tax rate. The third is the use of book values for invested capital, rather than market values. The final is the timing difference; the capital invested is from the end of the prior year whereas the operating income or EBIT is the current year's number.

Why is ROIC % important?

Because it costs money to raise capital. A firm that generates higher returns on investment than it costs the company to raise the capital needed for that investment is earning excess returns. A firm that expects to continue generating positive excess returns on new investments in the future will see its value increase as growth increases, whereas a firm that earns returns that do not match up to its cost of capital will destroy value as it grows.

As of today, C-Rad AB's WACC % is 7.40%. C-Rad AB's ROIC % is 19.75% (calculated using TTM income statement data). C-Rad AB generates higher returns on investment than it costs the company to raise the capital needed for that investment. It is earning excess returns. A firm that expects to continue generating positive excess returns on new investments in the future will see its value increase as growth increases. C-Rad AB earns returns that do not match up to its cost of capital. It will destroy value as it grows.


Be Aware

Like ROE % and ROA %, ROIC % is calculated with only 12 months of data. Fluctuations in the company's earnings or business cycles can affect the ratio drastically. It is important to look at the ratio from a long term perspective.


C-Rad AB ROIC % Related Terms

Thank you for viewing the detailed overview of C-Rad AB's ROIC % provided by GuruFocus.com. Please click on the following links to see related term pages.


C-Rad AB (LTS:0R44) Business Description

Traded in Other Exchanges
Address
Sjukhusvägen 12K, Uppsala, SWE, 753 09
C-Rad AB is a Sweden based company engaged in the development and sales of systems with applications in radiation therapy for the treatment of cancer. The systems can be used to position the patient before the treatment and to localize and monitor the tumor by recording information such as patient movements during radiation treatment. The operating segments of the group are the Positioning segment which includes development and sales of products in the field of patient positioning during radiotherapy, including catalyst, sentinel, and HIT lasers; and the Imaging segment which includes the development of imaging devices and detectors for cancer treatments and dosimetry. It generates maximum revenue from the Positioning segment. The firm sells its products in Sweden and internationally.

C-Rad AB (LTS:0R44) Headlines

No Headlines